PROM1 and neoplasm: The Han team injected MenSCs intratumorally or intravenously into an aggressive glioma rat model and yielded significant tumor inhibition, indicated by decreased angiogenesis and CD133+ cell number, a signature of tumor cells residing in hypoxic niche [60].